This week, US Magistrate Judge Richard Lloret directed Boehringer Ingelheim to disclose its launch plans for its biosimilar adalimumab, Cyltezo, as part of a long-running patent dispute with AbbVie, maker of the reference adalimumab, Humira.
This week, US Magistrate Judge Richard Lloret directed Boehringer Ingelheim (BI) to disclose its launch plans for its biosimilar adalimumab, Cyltezo, as part of a long-running patent dispute with AbbVie, maker of the reference adalimumab, Humira.
AbbVie filed a request to compel BI to detail its launch plans, saying that the plans are relevant to BI’s “unclean hands” defense, a legal defense that bars a party who is asking for a judgment from receiving the court’s help if that party has behaved unethically with respect to the subject of the lawsuit. According to BI, AbbVie’s strategy of acquiring what BI describes as overlapping, noninventive patents to hinder biosimilar competition could constitute unclean hands on AbbVie’s part.
According to AbbVie, BI’s public statements that it intends to launch Cyltezo prior to Humira’s patent expiry contradict BI’s claim that AbbVie’s patent estate has blocked BI from bringing its drug to the US market.
AbbVie also claims that BI is stockpiling Cyltezo ahead of a launch, an action that AbbVie says would infringe its patents.
BI, however, argues that the Biologics Price Competition and Innovation Act (BPCIA)’s provision of a 180-day notice of commercial marketing would be disrupted if the company were compelled to make its launch plans known to AbbVie.
Judge Lloret wrote in his memorandum that the BPCIA does not prevent or limit discovery in a biosimilar litigation, and that “Boehringer reads too much into the statute…the 180-day notice requirement is not designed to cloak launch plans with a broad ranging privilege against disclosure before the notice is filed.”
The judge also wrote that BI’s account of the motive behind and the consequences of AbbVie’s alleged misconduct related a patent thicket is central to its argument. The degree to which Humira’s patents delayed BI’s launch of its biosimilar “may have a legitimate impact on a fact-finder’s assessment of whether AbbVie has unclean hands,” he wrote. If BI argues that a patent thicket was created in order to delay competition and harm competitors, then it “would be unfair” for BI to refuse to quantify the damage caused.
Judge Lloret wrote that he will allow limited discovery and would require BI to state whether it contends that an alleged patent thicket delayed its launch plans for Cyltezo; if BI says that its plans were not delayed, “that will be an end to the discovery dispute.”
With respect to AbbVie’s concerns about BI’s alleged stockpiling of Cyltezo, however, the judge wrote that discovery would have minimal value and would pose a disproportionate burden, and he denied AbbVie’s request.
This latest development comes just weeks after Judge Lloret directed AbbVie to turn over to BI its documents related to its efforts to obtain patents on Humira. The judge agreed with BI that AbbVie had failed to produce numerous documents related to its patenting program and ordered AbbVie to “engage in rapid and punctilious compliance” with the order to produce the relevant materials.
Budget Impact Analysis of Biosimilar Natalizumab in the US
Projected savings from biosimilar natalizumab were $452,611 over 3 years, driven by decreased drug acquisition costs and a utilization shift from reference to biosimilar natalizumab.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Biosimilars Policy Roundup for April 2024—Podcast Edition
May 5th 2024On this episode of Not So Different, The Center for Biosimilars® glances back at all the major biosimilar policy updates from April, including 2 FDA approvals, 1 European approval, and several insights into possible policy changes from the Festival of Biologics USA conference.
Hesitancy in MENA Nations to Adopt WHO Biosimilar Guidelines Hinders Market Development
July 17th 2024The World Health Organization’s (WHO) new guidelines for biosimilar approvals aim to save time and money for manufacturers in the Middle East and North Africa (MENA), but hesitancy among nations to adopt the guidelines is stifling market development of biosimilars.
BioRationality: Time to Get Rid of PBMs if Biosimilars Are to Succeed
July 15th 2024Sarfaraz K. Niazi, PhD, discusses the challenges with pharmacy benefit managers (PBMs) that plague the biosimilar industry and new legislation that attempts to reform their practices and encourage biosimilar adoption.